Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Finotonlimab Combined With Cetuximab and Docetaxel as Neoadjuvant Therapy for Resectable Recurrent Head and Neck Squamous Cell Carcinoma After Immunotherapy Progression: A Multicenter, Single-Arm, Phase II Clinical Study

NCT07618624 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT07618624
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07618624 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Finotonlimab Combined With Cetuximab and Docetaxel as Neoadjuvant Therapy for Resectable Recurrent Head and Neck Squamous Cell Carcinoma After Immunotherapy Progression: A Multicenter, Single-Arm, Phase II Clinical Study
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Enrolling by invitation
Start date
April 20, 2026
Completion date
December 31, 2029
Enrollment
42 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer, recurrent head and neck squamous cell carcinoma